Last updated: April 2026
RU-58841 is a non-steroidal androgen receptor antagonist developed by Roussel Uclaf in the 1990s. Topically applied, it blocks DHT from binding to scalp follicle receptors without reducing systemic testosterone — the theoretical holy grail for treating male pattern baldness without sexual side effects. It was abandoned commercially, but never forgotten.
Male pattern baldness is driven by DHT binding to androgen receptors in scalp follicles, triggering miniaturization. RU-58841 blocks this at the receptor level — without affecting systemic androgen levels.
RU-58841 is a competitive antagonist at the androgen receptor (AR). It has high affinity for AR but doesn't activate it — it simply occupies the receptor, preventing DHT (and testosterone) from binding. In scalp follicles, this blocks the miniaturization signal. Ki values show strong AR binding comparable to other approved anti-androgens.
The key claimed advantage: after topical application, RU-58841 is rapidly metabolized in skin to an inactive form before reaching systemic circulation. Animal studies showed minimal systemic anti-androgenic effects at doses that achieved scalp AR saturation. This predicts topical specificity — but human PK data is limited and vehicle formulation affects absorption significantly.
Unlike finasteride (which reduces systemic DHT by ~70% via 5-alpha reductase inhibition), RU-58841 doesn't change DHT levels — it blocks the receptor. This means testosterone and DHT blood levels remain normal. The theoretical outcome: hair retention without reduced libido, sexual function, or the mood effects some finasteride users report (post-finasteride syndrome).
RU-58841 is chemically unstable, particularly in solution with propylene glycol/ethanol vehicles. It degrades over weeks to months depending on storage temperature. Community users report significant variability in effectiveness, partly attributable to purchasing or preparing degraded product. Pre-dissolved solutions should be refrigerated and have a limited shelf life.
The three main tools for androgenetic alopecia — how they compare on mechanism, evidence, and risk.
| Factor | RU-58841 | Finasteride | Minoxidil |
|---|---|---|---|
| Mechanism | AR antagonist (topical) | 5α-reductase inhibitor | Vasodilator / K+ channel |
| Systemic DHT effect | None (theoretically) | ↓70% systemic DHT | None |
| Route | Topical scalp only | Oral (1mg/day) | Topical or oral |
| FDA approval | None — research only | Approved (Propecia) | Approved (Rogaine) |
| Human trial evidence | Limited (P&G studies) | Extensive (decades) | Extensive (decades) |
| Sexual side effects | Low theoretical risk | ~2-5% in trials | Minimal |
| Stability | Poor — degrades in solution | Stable tablet | Stable solution |
| Cost | High (research chem) | Low (generic available) | Low (OTC) |
Evidence strength by research context. Most published data is preclinical; limited human data exists from Proctor & Gamble studies conducted in the 1990s.
Reported from community use and limited animal/human study data. Topical route significantly reduces systemic risk — but doesn't eliminate it.
Third-party HPLC tested with published COAs. One of the most established research peptide vendors.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Supplements with actual clinical evidence for hair health — useful alongside or instead of research chemicals for lower-risk protocols.
RU-58841 is not approved for human use. This content is educational only. Use of unapproved research chemicals carries unknown risks. Consult a dermatologist or physician for evidence-based hair loss treatment. HighPeptides does not recommend self-administration of research chemicals.